IASLC Atlases

Each of the four IASLC atlases shown below are produced by an expert panel and provides both health care practitioners and the public with greater understanding of lung cancer. 

The IASLC Atlas of EGFR Testing in Lung Cancer  is a useful guidebook, aiming to provide pathologists with “know-how” information on EGFR testing, and to provide the clinicians with the “know-why” information on how to interpret the results.

From the retrieval and handling of tumor sample to the different available assays, and from interpretation of results to reporting and quality assurance, the atlas is a comprehensive yet user friendly compendium for the general oncology readership.

The EGFR Atlas also summarizes the relevant clinical data supporting the application of EGFR testing in patients with either treatment-naïve or EGFR TKI-resistant disease.

The IASLC Atlas of EGFR Testing in Lung Cancer  is a useful guidebook, aiming to provide pathologists with “know-how” information on EGFR testing, and to provide the clinicians with the “know-why” information on how to interpret the results.

From the retrieval and handling of tumor sample to the different available assays, and from interpretation of results to reporting and quality assurance, the atlas is a comprehensive yet user friendly compendium for the general oncology readership.

The EGFR Atlas also summarizes the relevant clinical data supporting the application of EGFR testing in patients with either treatment-naïve or EGFR TKI-resistant disease.

The IASLC Atlas of PD-L1 Testing in Lung Cancer features an expert panel of authors and presents current information about the emerging PD-L1 IHC assays, as well as to highlight both areas of clarity and debate.

The authors of this atlas have approached this topic with a wide lens, looking at the the changing landscape of laboratory testing general as well as the specifics of each assay and current controversies in PD-L1 testing in lung cancer.
Although this atlas is designed primarily for physicians and others working in health care, it is the hope of the IASLC that it will also give patients more of a comprehensive understanding of the current biomarker situation and their treatment options.

The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer  was produced by an expert panel.

The Atlas is meant to serve as a resource to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced NSCLC.

The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer  was produced by an expert panel.

The Atlas is meant to serve as a resource to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced NSCLC.

The Pathology Committee of the International Association for the Study of Lung Cancer (IASLC) convened a panel of experts to publish the IASLC Atlas of ALK Testing in Lung Cancer, which can help pathologists, laboratory scientists and practicing physicians better understand the background, protocol, and interpretation of results of ALK testing in patients with advanced NSCLC.

In addition to English, the atlas is available in the following languages: Spanish | Chinese | Japanese.